CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
May 19 2021 - 09:20AM
Corbus Pharmaceuticals
Holdings,
Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a
clinical-stage drug development company pioneering transformative
medicines that target the endocannabinoid system, today announced
that it has adjourned its 2021 Annual Meeting of Stockholders (the
“Annual Meeting”) in order to provide stockholders additional time
within which to vote on all proposals, including Proposal 4 to
approve an amendment to the Company’s certificate of incorporation
to increase the Company’s authorized shares of common stock from
150,000,000 to 300,000,000.
The Company believes there is significant
support for Proposal 4. At the time of the Annual Meeting,
approximately 85% of the votes cast on Proposal 4 were voted in
favor of its approval. Because Proposal 4 must be approved by a
majority of the outstanding shares of common stock, however, it has
not yet received a sufficient number of votes in its favor. Because
Corbus’ Board of Directors continues to believe that Proposal 4 is
advisable and in the best interests of the Company’s stockholders
to consider and act upon Proposal 4, the Company adjourned the
Annual Meeting.
The adjourned meeting will be held at 9:00 a.m.
ET on Thursday, June 17, 2021 at the following url:
www.viewproxy.com/corbuspharma/2021/vm. The record date for the
annual meeting is March 31, 2021.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a
clinical-stage company focused on the development and
commercialization of novel medicines designed to target the
endocannabinoid system. The Company’s lead product candidate,
lenabasum, is a novel, oral, selective cannabinoid receptor type 2
(CB2) agonist designed to provide an alternative to
immunosuppressive medications in the treatment of chronic
inflammatory and fibrotic diseases. Lenabasum is currently being
evaluated in dermatomyositis and systemic lupus erythematosus.
Corbus is also developing a pipeline of other preclinical drug
candidates from its endocannabinoid system platform.
Lenabasum is not approved for the treatment of
any indication. For more information on Corbus’ clinical programs,
please visit here.
For more information,
visit http://www.corbuspharma.com/, and connect with us
on Twitter, LinkedIn, and Facebook.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
CommunicationsPhone: +1 (617)
415-7745Email: ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate
CommunicationsPhone: +1 (617)
415-7749Email: mediainfo@corbuspharma.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2023 to Mar 2024